JP2002519391A - 痛みを処置するための、プロテインキナーゼｃイプシロンの阻害剤の使用 - Google Patents

痛みを処置するための、プロテインキナーゼｃイプシロンの阻害剤の使用

Info

Publication number
JP2002519391A
JP2002519391A JP2000557861A JP2000557861A JP2002519391A JP 2002519391 A JP2002519391 A JP 2002519391A JP 2000557861 A JP2000557861 A JP 2000557861A JP 2000557861 A JP2000557861 A JP 2000557861A JP 2002519391 A JP2002519391 A JP 2002519391A
Authority
JP
Japan
Prior art keywords
pkcε
pain
epinephrine
inhibitor
hyperalgesia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000557861A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002519391A5 (https=
Inventor
オー． メッシング，ロバート
ディー． ルバイン，ジョン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2002519391A publication Critical patent/JP2002519391A/ja
Publication of JP2002519391A5 publication Critical patent/JP2002519391A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
JP2000557861A 1998-07-06 1999-07-06 痛みを処置するための、プロテインキナーゼｃイプシロンの阻害剤の使用 Pending JP2002519391A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US9175598P 1998-07-06 1998-07-06
US60/091,755 1998-07-06
US10376398P 1998-10-09 1998-10-09
US60/103,763 1998-10-09
PCT/US1999/015265 WO2000001415A2 (en) 1998-07-06 1999-07-06 Use of inhibitors of protein kinase c epsilon to treat pain

Publications (2)

Publication Number Publication Date
JP2002519391A true JP2002519391A (ja) 2002-07-02
JP2002519391A5 JP2002519391A5 (https=) 2005-06-02

Family

ID=26784298

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000557861A Pending JP2002519391A (ja) 1998-07-06 1999-07-06 痛みを処置するための、プロテインキナーゼｃイプシロンの阻害剤の使用

Country Status (10)

Country Link
EP (1) EP1093379B1 (https=)
JP (1) JP2002519391A (https=)
AT (1) ATE350032T1 (https=)
AU (1) AU764760B2 (https=)
CA (1) CA2336709A1 (https=)
DE (1) DE69934689T2 (https=)
ES (1) ES2283120T3 (https=)
IL (1) IL140716A0 (https=)
NZ (1) NZ508767A (https=)
WO (1) WO2000001415A2 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006525948A (ja) * 2003-05-16 2006-11-16 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 離脱症状における使用のためのプロテインキナーゼｃペプチド
JP2010090176A (ja) * 2010-01-26 2010-04-22 Board Of Trustees Of The Leland Stanford Junior Univ 離脱症状における使用のためのプロテインキナーゼｃペプチド
JPWO2014081029A1 (ja) * 2012-11-26 2017-01-05 学校法人近畿大学 抗がん剤による末梢神経障害の予防、治療、または軽減剤

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7790192B2 (en) 1998-08-14 2010-09-07 Accessclosure, Inc. Apparatus and methods for sealing a vascular puncture
AU2003234185C1 (en) 2002-04-22 2009-11-19 The Board Of Trustees Of The Leland Stanford Junior University Peptide inhibitors of protein kinase C
US6933275B2 (en) 2002-05-01 2005-08-23 The Board Of Trustees Of The Leland Stanford Junior University Protein kinase C peptides for use in withdrawal
WO2004084889A1 (en) * 2003-03-28 2004-10-07 Pfizer Inc. Use of protein kinase c inhibitor for suppressing sustained slow postsynaptic excitation (sspe) of enteric neurons
EP1670497A4 (en) 2003-09-16 2009-07-15 Garvan Inst Med Res METHOD FOR IDENTIFYING MODULATORS OF PROTEIN KINASE C EPSILON (PKC Ε) AND METHOD FOR TREATING THEREOF CONVERTING DERIVED GLUCOSE METABOLISM
WO2006095086A2 (fr) * 2005-03-07 2006-09-14 Laurence Faure Traçabilite des anomalies du cycle cellulaire ciblant l'oncologie et la neurodegenerescence.
EP1869205B1 (en) * 2005-04-02 2010-07-14 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Assays for determining compounds which modulate tram phosphorylation
US8575307B2 (en) 2005-06-29 2013-11-05 Hadasit Medical Research Services & Development Ltd. Protein kinase C inhibitors for prevention of insulin resistance and type 2 diabetes
EP2177510A1 (en) 2008-10-17 2010-04-21 Universität des Saarlandes Allosteric protein kinase modulators
US8785648B1 (en) 2010-08-10 2014-07-22 The Regents Of The University Of California PKC-epsilon inhibitors
EP3180003B1 (en) 2014-07-01 2022-01-12 The Regents of the University of California Pkc-epsilon inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5141957A (en) * 1990-11-02 1992-08-25 Sphinx Pharmaceuticals Corporation 1,4-bis-(amino-hydroxyalkylamino)-anthraquinones for inhibiting protein kinase c
US5783405A (en) * 1994-02-01 1998-07-21 Terrapin Technologies, Inc. Rapid screening method for effectors of signal transduction
WO1997015575A1 (en) * 1995-10-27 1997-05-01 Procyon Pharmaceuticals, Inc. Protein kinase c modulators. y.

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006525948A (ja) * 2003-05-16 2006-11-16 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 離脱症状における使用のためのプロテインキナーゼｃペプチド
JP2010090176A (ja) * 2010-01-26 2010-04-22 Board Of Trustees Of The Leland Stanford Junior Univ 離脱症状における使用のためのプロテインキナーゼｃペプチド
JPWO2014081029A1 (ja) * 2012-11-26 2017-01-05 学校法人近畿大学 抗がん剤による末梢神経障害の予防、治療、または軽減剤

Also Published As

Publication number Publication date
ES2283120T3 (es) 2007-10-16
AU4863199A (en) 2000-01-24
EP1093379A2 (en) 2001-04-25
WO2000001415A2 (en) 2000-01-13
WO2000001415A3 (en) 2000-04-13
EP1093379B1 (en) 2007-01-03
DE69934689D1 (de) 2007-02-15
ATE350032T1 (de) 2007-01-15
DE69934689T2 (de) 2007-10-25
AU764760B2 (en) 2003-08-28
IL140716A0 (en) 2002-02-10
CA2336709A1 (en) 2000-01-13
NZ508767A (en) 2003-12-19

Similar Documents

Publication Publication Date Title
US6686334B2 (en) Use of inhibitors of protein kinase C epsilon to treat pain
US10485845B2 (en) Neuronal pain pathway
Wu et al. Functional up‐regulation of P2X3 receptors in dorsal root ganglion in a rat model of bone cancer pain
Soriano et al. Specific targeting of pro-death NMDA receptor signals with differing reliance on the NR2B PDZ ligand
Fundytus et al. Knockdown of spinal metabotropic glutamate receptor 1 (mGluR1) alleviates pain and restores opioid efficacy after nerve injury in rats
Li et al. TNF-α acts via p38 MAPK to stimulate expression of the ubiquitin ligase atrogin1/MAFbx in skeletal muscle
JP2002519391A (ja) 痛みを処置するための、プロテインキナーゼｃイプシロンの阻害剤の使用
Xu et al. Extracellular signal-regulated protein kinase activation in spinal cord contributes to pain hypersensitivity in a mouse model of type 2 diabetes
Aira et al. Transient, 5-HT2B receptor–mediated facilitation in neuropathic pain: Up-regulation of PKCγ and engagement of the NMDA receptor in dorsal horn neurons
Lyons et al. Combination drug therapy of pioglitazone and D-cycloserine attenuates chronic orofacial neuropathic pain and anxiety by improving mitochondrial function following trigeminal nerve injury
Aira et al. Synaptic upregulation and superadditive interaction of dopamine D2-and μ-opioid receptors after peripheral nerve injury
US12329756B2 (en) Regulation of eIF4E activity for migraine therapy
Bessero et al. Role of the c‐Jun N‐terminal kinase pathway in retinal excitotoxicity, and neuroprotection by its inhibition
JP2010516709A (ja) 疼痛減弱のためのイプシロン阻害化合物の使用方法
JP6698358B2 (ja) 汗分泌促進剤及び該汗分泌促進剤を含有するドライスキンの予防薬又は治療薬
JP2009536950A (ja) 末梢神経障害を治療および予防するための方法および組成物
Juránek et al. Evidence for the participation of glutamate in reflexes involving afferent, substance P‐containing nerve fibres in the rat
Clement et al. ATP-Sensitive Potassium Channels in Migraine: Translational Findings and Therapeutic Potential. Cells 2022, 11, 2406
Izraylev Cannabinoid 1 Receptor Activation Prevents Latent Sensitization in an Animal Model of Medication Overuse Headache
Cline Role of pituitary adenylate cyclase-activating polypeptide in energy expenditure including the thermogenic response
Arulmani Calcitonin gene-related peptide and migraine: Implications for therapy
Molander et al. Neurochemical characterization of neuronal populations expressing protein kinase C gamma isoform in the spinal cord and gracile nucleus of the rat
Morris Regulation of EGFR by the NF2 tumor suppressor, Merlin
Vadakkan Development of animal models and characterization of molecular mechanisms in muscle and neuropathic pain
Arulmani Calcitonin gene-related peptide and migraine

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20061128

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20070227

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20070313

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20070717